Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy

Published:2017-08 Issue:15 Volume:25 Page:4100-4109
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Yuan Zigao,Chen Shaopeng,Sun Qinsheng,Wang Ning,Li Dan,Miao Shuangshuang,Gao Chunmei,Chen Yuzong,Tan Chunyan,Jiang Yuyang

Funder

Chinese National Natural Science Foundation

Shenzhen Sci & Tech Bureau

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference53 articles.

1. An update on PARP inhibitors—moving to the adjuvant setting;Sonnenblick;Nat Rev Clin Oncol,2014

2. Biology of poly(ADP-Ribose) polymerases: the factotums of cell maintenance;Bai;Molecular Cell,2015

3. BRCAness revisited;Lord;Nat Rev Cancer,2016

4. PARP inhibitors: synthetic lethality in the clinic;Lord;Science,2017

5. PARP inhibitors as antitumor agents: a patent update (2013–2015);Yuan;Expert Opin Ther Pat,2017

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors;Bioorganic Chemistry;2024-10

2. Overview of class I HDAC modulators: Inhibitors and degraders;European Journal of Medicinal Chemistry;2024-10

3. Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies;Biomedicine & Pharmacotherapy;2024-09

4. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer;Frontiers in Oncology;2024-08-02

5. Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth;PLOS ONE;2024-07-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3